Piper Jaffray analyst Joshua Schimmer was out pounding the table on Gilead Sciences, Inc. (NASDAQ:GILD) Friday, reiterating an Overweight rating and raising the price target to $131 …
Gilead Sciences, Inc. (NASDAQ:GILD) will release second quarter earnings on Tuesday, July 28.
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen …
Second quarter earnings season is upon us and Cowen & Co. is counting on the biotechnology sector to deliver.
Herein we discuss several important drivers for Gilead Sciences, Inc. (NASDAQ:GILD) shares going into 2Q15/2016.
Recently, various executives have taken part in insider selling activity for the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), Facebook Inc (NASDAQ:FB), Intercept Pharmaceuticals …
Maxim Group analyst Jason Kolbert came out today with a research report on Gilead Sciences, Inc. (NASDAQ:GILD), reiterating a Buy rating and a price target …
Well, the Greek Debt Crisis has come to a conclusion, a default; and US stocks seem to be back to normal. This leaves …
Recently, various executives have taken part in insider selling activity for the stocks of Tesla Motors Inc (NASDAQ:TSLA), Gilead Sciences, Inc (NASDAQ:GILD), Palo Alto Networks Inc …
Recently, various executives have taken part in insider selling activity for the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Twitter Inc (NYSE:TWTR), …
